A new study says that by 2030, about half of all adults worldwide with type 2 diabetes won't have access to insulin. The life-saving drug helps diabetics stave off amputation, blindness, kidney failure, and stroke. According to UPI, only three companies currently produce insulin: Novo Nordisk, Sanofi and Lilly. Climbing global rates of diabetes, and growing numbers of people living with the disease, drive both demand and prices for insulin.
